RNA Targeting Small Molecule Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others), By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others), By Region and By Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

The Global RNA Targeting Small Molecule Drug Discovery Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the increasing prevalence of diseases such as cancer, genetic disorders, and viral infections and rising expenditure in R&D activities by pharmaceutical and biotechnology businesses. Also, the growing presence of key market players, advanced healthcare infrastructure, and increasing investment in research and development activities are expected to create lucrative growth during the forecast period. Similarly, a growing well-established healthcare system that supports the development and commercialization of new therapies is also a major factor fuelling the growth of the market over the years. In fact, in 2020, the USFDA approved 55 drugs, of which, over 65% were small molecule therapeutics. It is worth noting that majority of these drugs were conventionally developed to target proteins.

Increasing Prevalence of RNA-Related Diseases

The increasing prevalence of RNA-related diseases is one of the key drivers of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. RNA plays a critical role in various cellular processes, and dysregulation of RNA function can lead to various diseases, including cancer, genetic disorders, and viral infections. The prevalence of these diseases is increasing, leading to a growing demand for RNA-targeted small molecule drugs. RNA-targeted small molecule drugs offer a promising approach for the treatment of RNA-related diseases. Small molecules can selectively bind to specific RNA targets and modulate their activity, offering a potential therapeutic approach for diseases caused by RNA dysregulation. For example, RNA-targeted small molecule drugs have shown promising results in the treatment of cancer, particularly in cases where traditional chemotherapy is not effective. They have also shown potential for the treatment of genetic disorders caused by RNA abnormalities, such as cystic fibrosis. The increasing prevalence of RNA-related diseases has led to an increased focus on RNA-targeted small molecule drug discovery research. Many pharmaceutical companies, startups, and research institutions are investing heavily in this area, which is driving the growth of the market.

Advancements in RNA Biology

Advancements in RNA biology have played a significant role in the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. With the advancement of technologies, including high-throughput sequencing and gene editing, the understanding of RNA biology has increased significantly. This has led to the identification of new RNA targets and the development of novel RNA-targeted small molecule drugs. Advancements in RNA biology have enabled researchers to better understand the mechanisms by which RNA molecules contribute to disease. This understanding has led to the identification of new RNA targets that were previously unknown or poorly understood. The discovery of new RNA targets has opened up new opportunities for drug discovery, leading to the development of novel RNA-targeted small molecule drugs. Furthermore, advancements in RNA biology have led to the development of new technologies and tools for RNA-targeted small molecule drug discovery. For example, advances in high-throughput screening technologies have enabled researchers to screen large libraries of compounds to identify potential RNA-targeted drugs quickly. This has accelerated the drug discovery process and enabled the development of new drugs more efficiently. Advancements in RNA biology have also enabled the development of RNA-targeted small molecule drugs with improved specificity and potency. By understanding the structure and function of RNA molecules, researchers can design small molecules that selectively bind to specific RNA targets and modulate their activity.

Increased Funding for RNA-Targeted Drug Discovery Research

Increased funding for RNA-targeted drug discovery research has a significant impact on the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. RNA-targeted small molecule drugs offer a promising approach for the treatment of various diseases, including cancer, genetic disorders, and viral infections. However, developing these drugs is a complex process that requires significant investment in research and development. Increased funding for RNA-targeted drug discovery research can help to accelerate the drug discovery process and improve the chances of success. Funding can support research in identifying and validating RNA targets, developing new screening technologies, designing small molecules, and conducting preclinical and clinical studies. Furthermore, increased funding can help to attract top researchers and scientists to the field, leading to more innovation and breakthroughs in RNA-targeted drug discovery research. The availability of funding can also encourage collaborations between academia and industry, leading to more efficient and effective drug discovery processes. Several organizations, including governments, non-profit organizations, and pharmaceutical companies, are investing heavily in RNA-targeted drug discovery research. For example, the US National Institutes of Health (NIH) has launched several initiatives aimed at accelerating RNA-targeted drug discovery, including the RNA-focused Accelerating Medicines Partnership and the Blueprint Neurotherapeutics Network. These initiatives provide significant funding and resources for researchers working in the field.

Growing Demand for Personalized Medicine

The growing demand for personalized medicine is a significant driver of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. Personalized medicine aims to tailor medical treatment to the individual characteristics of each patient, taking into account their genetic makeup, lifestyle, and environment. RNA-targeted small molecule drugs offer a promising approach for personalized medicine, as they can selectively target specific RNA molecules that are involved in a patient's disease. RNA-targeted small molecule drugs can be designed to be specific to individual patients' genetic profiles, leading to more effective treatments and better patient outcomes. For example, a patient with cancer may have a specific mutation in their RNA that is driving the growth of their tumor. RNA-targeted small molecule drugs can be designed to specifically target this mutation, leading to more effective treatment and fewer side effects. Furthermore, RNA-targeted small molecule drugs can be used to treat rare diseases caused by specific RNA abnormalities. These drugs can be developed and manufactured in small quantities, making them ideal for personalized medicine. The growing demand for personalized medicine is driven by several factors, including advances in genomic medicine, increasing patient awareness and demand for more personalized care, and improvements in technology for developing and manufacturing personalized therapies. Many pharmaceutical companies and startups are investing in RNA-targeted small molecule drug discovery research to meet the growing demand for personalized medicine. These companies are leveraging advancements in RNA biology, high-throughput screening technologies, and computational methods to develop personalized RNA-targeted small molecule drugs.

Rise in the Number of Startups and Small Companies Focusing on RNA-Targeted Drug Discovery

The rise in the number of startups and small companies focusing on RNA-targeted drug discovery is a significant driver of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. Startups and small companies are playing a crucial role in advancing RNA-targeted drug discovery research and bringing innovative therapies to the market. Startups and small companies are often more agile and able to quickly adopt new technologies and approaches to drug discovery. These companies can focus on niche areas of RNA biology, allowing them to identify and develop RNA targets that may have been overlooked by larger pharmaceutical companies. Furthermore, startups and small companies are increasingly receiving funding and support from venture capitalists, government agencies, and non-profit organizations. This funding allows these companies to invest in research and development and advance their pipeline of RNA-targeted small molecule drugs. The rise of startups and small companies in the RNA-targeted drug discovery space is also leading to increased competition, which is driving innovation and improving the efficiency of the drug discovery process. This competition is also leading to the development of more affordable and accessible RNA-targeted small molecule drugs, which can benefit patients globally. Several startups and small companies focusing on RNA-targeted drug discovery have already made significant advances in the field. These companies have developed innovative screening platforms, identified novel RNA targets, and advanced promising RNA-targeted small molecule drugs into preclinical and clinical trials.

Recent Development

  • In 2021, the US FDA approved the first RNA-targeted small molecule drug, Lumasiran, for the treatment of primary hyperoxaluria type 1. Lumasiran targets and degrades the RNA that encodes the enzyme responsible for producing oxalate, which accumulates in patients with this rare genetic disease. This approval represents a significant milestone for the RNA-targeted drug discovery field.
  • In 2020, Alnylam Pharmaceuticals launched Lumasiran, the first RNA-targeting small molecule drug approved by the US FDA. Lumasiran is indicated for the treatment of primary hyperoxaluria type 1, a rare genetic disorder that can lead to kidney damage and failure.
  • In 2019, Alnylam Pharmaceuticals launched Givosiran, an RNA-targeting small molecule drug for the treatment of acute hepatic porphyria. Givosiran works by targeting and degrading the RNA that encodes the enzyme responsible for producing toxic heme intermediates in patients with this rare genetic disease.
  • In 2021, Novartis launched Inclisiran, an RNA-targeting small molecule drug for the treatment of high cholesterol. Inclisiran targets and degrades the RNA that encodes for PCSK9, a protein that regulates cholesterol levels in the blood.


Download Free Sample Report

Market Segmentation

Global RNA Targeting Small Molecule Drug Discovery market can be segmented by Indication, End Users, Region and Competitive Landscape. Based on the indication, the market can be segmented into Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others. Based on end users, the market can be differentiated into Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others.

Market Players

Accent Therapeutics., Anima Biotech Inc., Arrakis Therapeutics., AstraZeneca., Epics Therapeutics., Expansion Therapeutics., Hoffmann-La Roche Ltd., H3 Biomedicine Inc., PTC Therapeutics., Ribometrix., Servier Laboratories., Skyhawk Therapeutics, Inc. are some of the leading players operating in the Global RNATargeting Small Molecule Drug Discovery Market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

By Indication

By End Users

By Region

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE

Key companies profiled

Accent Therapeutics., Anima Biotech Inc., Arrakis Therapeutics., AstraZeneca., Epics Therapeutics., Expansion Therapeutics., Hoffmann-La Roche Ltd., H3 Biomedicine Inc., PTC Therapeutics., Ribometrix., Servier Laboratories., Skyhawk Therapeutics, Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, Global RNA Targeting Small Molecule Drug Discovery market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

        ·         RNA Targeting Small Molecule Drug Discovery Market, By Indication:

o    Cancer

o    Infectious Diseases

o    Metabolic Diseases

o    Neurological Diseases

o    Other

        ·         RNA Targeting Small Molecule Drug Discovery Market, By End Users:

o   Pharmaceutical and Biopharmaceutical Companies

o   Academic and Research Institutes

o   Others

        ·         RNA Targeting Small Molecule Drug Discovery Market, By Region:

o    North America

§  United States

§  Canada

§  Mexico

o    Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o    Asia Pacific

§  China

§  India

§  Japan

§  South Korea

§  Australia

o    South America

§  Brazil

§  Argentina

§  Colombia

o    Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Targeting Small Molecule Drug Discovery Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global RNA Targeting Small Molecule Drug Discovery Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global RNA Targeting Small Molecule Drug Discovery Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)

5.2.2.     By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)

5.2.3.     By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

5.2.4.     By Company (2022)

5.3.  Market Map

5.3.1 By Indication

5.3.2 By End Users

5.3.3 By Region

6.    North America RNA Targeting Small Molecule Drug Discovery Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)

6.2.2.     By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)

6.2.3.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States RNA Targeting Small Molecule Drug Discovery Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Indication

6.3.1.2.2.             By End User

6.3.2.     Canada RNA Targeting Small Molecule Drug Discovery Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Indication

6.3.2.2.2.             By End User

6.3.3.     Mexico RNA Targeting Small Molecule Drug Discovery Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Indication

6.3.3.2.2.             By End User

7.    Europe RNA Targeting Small Molecule Drug Discovery Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)

7.2.2.     By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)

7.2.3.     By Country

7.3.  Europe: Country Analysis

7.3.1.     France RNA Targeting Small Molecule Drug Discovery Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Indication

7.3.1.2.2.             By End User

7.3.2.     Germany RNA Targeting Small Molecule Drug Discovery Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Indication

7.3.2.2.2.             By End User

7.3.3.     United Kingdom RNA Targeting Small Molecule Drug Discovery Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Indication

7.3.3.2.2.             By End User

7.3.4.     Italy RNA Targeting Small Molecule Drug Discovery Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Indication

7.3.4.2.2.             By End User

7.3.5.     Spain RNA Targeting Small Molecule Drug Discovery Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Indication

7.3.5.2.2.             By End User

8.    Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)

8.2.2.     By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)

8.2.3.     By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.     China RNA Targeting Small Molecule Drug Discovery Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Indication

8.3.1.2.2.             By End User

8.3.2.     India RNA Targeting Small Molecule Drug Discovery Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Indication

8.3.2.2.2.             By End User

8.3.3.     Japan RNA Targeting Small Molecule Drug Discovery Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Indication

8.3.3.2.2.             By End User

8.3.4.     South Korea RNA Targeting Small Molecule Drug Discovery Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Indication

8.3.4.2.2.             By End User

8.3.5.     Australia RNA Targeting Small Molecule Drug Discovery Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Indication

8.3.5.2.2.             By End User

9.    South America RNA Targeting Small Molecule Drug Discovery Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)

9.2.2.     By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)

9.2.3.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil RNA Targeting Small Molecule Drug Discovery Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Indication

9.3.1.2.2.             By End User

9.3.2.     Argentina RNA Targeting Small Molecule Drug Discovery Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Indication

9.3.2.2.2.             By End User

9.3.3.     Colombia RNA Targeting Small Molecule Drug Discovery Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Indication

9.3.3.2.2.             By End User

10.  Middle East and Africa RNA Targeting Small Molecule Drug Discovery Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)

10.2.2.  By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)

10.2.3.  By Country

10.3.              MEA: Country Analysis

10.3.1.  South Africa RNA Targeting Small Molecule Drug Discovery Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Indication

10.3.1.2.2.           By End User

10.3.2.  Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Indication

10.3.2.2.2.           By End User

10.3.3.  UAE RNA Targeting Small Molecule Drug Discovery Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Indication

10.3.3.2.2.           By End User

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Development

12.2.              Mergers & Acquisitions

12.3.              Product Launches

13.  Global RNA Targeting Small Molecule Drug Discovery Market: SWOT Analysis

14.  Porter’s Five Forces Analysis

14.1.              Competition in the Industry

14.2.              Potential of New Entrants

14.3.              Power of Suppliers

14.4.              Power of Customers

14.5.              Threat of Substitute Products

15.  Competitive Landscape

15.1.              Business Overview

15.2.              Product Offerings

15.3.              Recent Developments

15.4.              Financials (As Reported)

15.5.              Key Personnel

15.6.              SWOT Analysis

15.6.1    Accent Therapeutics, Inc.

15.6.2    Anima Biotech Inc.

15.6.3    Arrakis Therapeutics, Inc.

15.6.4    AstraZeneca Plc.

15.6.5    Epics Therapeutics, Inc.

15.6.6    Expansion Therapeutics, Inc.

15.6.7    F.Hoffmann-La Roche AG

15.6.8    H3 Biomedicine Inc.

15.6.9    PTC Therapeutics, Inc.

15.6.10 Ribometrix, Inc.

16.   Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The increasing prevalence of diseases such as cancer, genetic disorders, and viral infections and growing investment in RNA-targeting small molecule drug discovery by market players are some of the major factors driving the growth of the Global RNA Targeting Small Molecule Drug Discovery market.

down-arrow

Accent Therapeutics., Anima Biotech Inc., Arrakis Therapeutics., AstraZeneca., Epics Therapeutics., Expansion Therapeutics., Hoffmann-La Roche Ltd., H3 Biomedicine Inc., PTC Therapeutics., Ribometrix., Servier Laboratories., Skyhawk Therapeutics, Inc. are some of the leading players operating in the Global RNA Targeting Small Molecule Drug Discovery Market.

down-arrow

The cancer segment is expected to dominate the Global RNA Targeting Small Molecule Drug Discovery market during the forecast period due to increase in the utilization of advanced technologies like combinational chemistry, bioinformatics and high throughput for better drug detection.

down-arrow

North American region is expected to hold the largest share in the Global RNA Targeting Small Molecule Drug Discovery Market due to the increasing government support for research and development activities.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

RNA Targeting Small Molecule Drug Discovery Market to be dominated by Cancer Segment through 2028

Jul, 2023

The increasing prevalence of RNA-related diseases is expected to drive the growth of Global RNA Targeting Small Molecule Drug Discovery Market during the forecast period, 2024-2028.

Why Choose Us